Is Compounded Ipamorelin / CJC-1295 Safe and Legal?
Compounded Ipamorelin / CJC-1295 is not currently available through Compounding Finder. Ipamorelin and CJC-1295 are not FDA-approved and are not on the FDA 503A bulk substances list, so US compounding pharmacies cannot legally dispense them for human consumption.
Read the Ipamorelin / CJC-1295 background guide →The Short Answer
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US compounding pharmacies can only compound from FDA-approved active ingredients, substances with a USP or NF monograph, or substances on the FDA 503A bulk substances list. Ipamorelin / CJC-1295 does not meet any of these criteria, so a licensed US compounding pharmacy cannot legally prepare or dispense it for human consumption — even with a prescription. Products marketed as Ipamorelin / CJC-1295 outside this framework generally come from research-chemical suppliers and are not regulated for human use.
Who Is Eligible for Compounded Ipamorelin / CJC-1295?
- There is no clinical eligibility pathway for Ipamorelin / CJC-1295 through 503A compounding at this time.
- If your prescriber has recommended Ipamorelin / CJC-1295, ask about FDA-approved alternatives that address the same condition.
- If FDA guidance changes and Ipamorelin / CJC-1295 is added to the 503A bulks list in the future, Compounding Finder will revisit routing.
Safety Considerations
- Only purchase prescription medications from U.S.-licensed compounding pharmacies for medications that are legally compoundable.
- Research-chemical peptide vendors and overseas "pharmacies" selling Ipamorelin / CJC-1295 for human use are not regulated — product identity, purity, sterility, and dosing are not verified.
- Any provider willing to prescribe or source a non-compoundable substance through these channels is operating outside the US 503A framework.
Red Flags: What to Avoid
- Any online clinic, telehealth provider, or vendor offering to "compound" or ship Ipamorelin / CJC-1295 for human use.
- Labeling that calls a product "research use only" or "not for human consumption" while simultaneously marketing it for human indications.
- Pharmacies that fulfill a prescription for an ingredient not on the FDA 503A bulks list — they are operating outside federal rules.
Frequently Asked Questions
Can any US compounding pharmacy prepare Ipamorelin / CJC-1295 for me?
No. Ipamorelin / CJC-1295 is not FDA-approved and is not on the FDA 503A bulk substances list. Licensed US 503A pharmacies are only permitted to compound from FDA-approved APIs, USP/NF monograph substances, or substances on the 503A bulks list. A prescription for Ipamorelin / CJC-1295 cannot be legally filled by a 503A pharmacy regardless of what the prescription says.
Why is Compounding Finder not sending Ipamorelin / CJC-1295 quote requests to pharmacies?
We only refer patients to licensed US 503A pharmacies. Sending a Ipamorelin / CJC-1295 quote request to those pharmacies would put them in a position to either decline or to fill a prescription they are not legally permitted to fill. Neither outcome is useful to the patient, so we do not route these requests.
What should I do if my prescriber recommended this?
Ask them whether an FDA-approved medication addresses the same underlying condition — for many of these peptides there are FDA-approved alternatives worth discussing. If the recommendation came from a wellness or telehealth clinic that also sells the product, be skeptical; that is not the same regulatory channel as a licensed US 503A compounding pharmacy.
Keep Reading
Pharmacy basics: 503A vs 503B pharmacies — what's the difference? →
Vetting pharmacies: How to find a reputable compounding pharmacy →
Overview: Compounded Ipamorelin / CJC-1295 — overview & pricing →
Compare prices: Compare Ipamorelin / CJC-1295 pricing from licensed pharmacies →
We Do Not Currently Route Ipamorelin / CJC-1295 Quote Requests
Because of the FDA’s current stance on Ipamorelin / CJC-1295, Compounding Finder is not sending Ipamorelin / CJC-1295 quote requests to our pharmacy network at this time. If FDA guidance changes, we will revisit.